Gene, Cell and Tissue

Published by: Kowsar

Lack of Association Between IL-1 Receptor Antagonist Gene 86bp VNTR Polymorphism and Leiomyoma

Milad Mohammadoo Khorasani 1 , 2 , Saeedeh Salimi 2 , 3 , * , Azam Hajizade 1 , 2 , Maryam Moossavi 4 , Ehsan Tabatabai 1 , 2 , Minoo Yaghmaei 5 , Lida Namazi 5 and Farzaneh Farajian Mashhadi 3 , 6
Authors Information
1 Student Scientific Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
4 Department of Biology, University of Sistan and Baluchestan, Zahedan, IR Iran
5 Department of Obstetrics and Gynecology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
6 Department of Pharmacology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Gene, Cell and Tissue: April 01, 2014, 1 (1); e18310
  • Published Online: April 8, 2014
  • Article Type: Research Article
  • Received: November 19, 2013
  • Revised: February 15, 2014
  • Accepted: February 17, 2014
  • DOI: 10.17795/gct-18310

To Cite: Mohammadoo Khorasani M, Salimi S, Hajizade A, Moossavi M, Tabatabai E, et al. Lack of Association Between IL-1 Receptor Antagonist Gene 86bp VNTR Polymorphism and Leiomyoma, Gene Cell Tissue. 2014 ; 1(1):e18310. doi: 10.17795/gct-18310.

Abstract
Copyright © 2014, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Marino JL, Eskenazi B, Warner M, Samuels S, Vercellini P, Gavoni N, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod. 2004; 19(10): 2350-5[DOI][PubMed]
  • 2. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007; 87(4): 725-36[DOI][PubMed]
  • 3. Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med. 2004; 22(2): 105-11[DOI][PubMed]
  • 4. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician. 2007; 75(10): 1503-8[PubMed]
  • 5. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003; 111(8): 1037-54[PubMed]
  • 6. Inagaki N, Ung L, Otani T, Wilkinson D, Lopata A. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. Eur J Obstet Gynecol Reprod Biol. 2003; 111(2): 197-203[PubMed]
  • 7. Sumitani H, Shozu M, Segawa T, Murakami K, Yang HJ, Shimada K, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology. 2000; 141(10): 3852-61[DOI][PubMed]
  • 8. Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of leiomyomata after myomectomy. Hum Reprod Update. 2000; 6(6): 595-602[PubMed]
  • 9. Malyshkina AI, Posiseeva LV, Sotnikova NY, Antsiferova JS, Suvorkina EE, Arevadze IE. Local immunological markers of different rate of growth of uterine myoma. Russ J Immunol. 2002; 7(1): 58-62[PubMed]
  • 10. Yun AJ, Daniel SM. Sympathetic and T helper (Th)2 bias may ameliorate uterine fibroids, independent of sex steroids. Med Hypotheses. 2005; 65(6): 1172-5[DOI][PubMed]
  • 11. Hsieh YY, Chang CC, Tsai CH, Lin CC, Tsai FJ. Interleukin (IL)-12 receptor beta1 codon 378 G homozygote and allele, but not IL-1 (beta-511 promoter, 3953 exon 5, receptor antagonist), IL-2 114, IL-4-590 intron 3, IL-8 3'-UTR 2767, and IL-18 105, are associated with higher susceptibility to leiomyoma. Fertil Steril. 2007; 87(4): 886-95[DOI][PubMed]
  • 12. Pietrowski D, Thewes R, Sator M, Denschlag D, Keck C, Tempfer C. Uterine leiomyoma is associated with a polymorphism in the interleukin 1-beta gene. Am J Reprod Immunol. 2009; 62(2): 112-7[DOI][PubMed]
  • 13. Sosna O, Kolesar L, Slavcev A, Skibova J, Fait T, Mara M, et al. Th1/Th2 cytokine gene polymorphisms in patients with uterine fibroid. Folia Biol (Praha). 2010; 56(5): 206-10[PubMed]
  • 14. Patterson D, Jones C, Hart I, Bleskan J, Berger R, Geyer D, et al. The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics. 1993; 15(1): 173-6[DOI][PubMed]
  • 15. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998; 16: 27-55[DOI][PubMed]
  • 16. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol. 1998; 47(3): 195-8[PubMed]
  • 17. Sikorski R, Kapec E, Zaleska W. [Serum levels of proinflammatory cytokines in women with uterine myomas]. Ginekol Pol. 2001; 72(12A): 1485-8[PubMed]
  • 18. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol. 1996; 156(1): 238-45[PubMed]
  • 19. Corbacioglu S, Pietsch T, Koenig A, Welte K. Interleukin-1 receptor antagonist: a powerful inhibitor of tumor vascularization and tumor growth in vivo. Anderson Cancer Center. 1994; 6: 35
  • 20. Van Le L, Haskill S, Jaffe GJ, Fowler WC, Jr.. Expression of interleukin-1 and interleukin-1 receptor antagonists in endometrial cancer. Gynecol Oncol. 1991; 42(2): 161-4[PubMed]
  • 21. Iizuka N, Hazama S, Hirose K, Abe T, Tokuda N, Fukumoto T, et al. Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett. 1999; 142(2): 179-84[PubMed]
  • 22. Vamvakopoulos J, Green C, Metcalfe S. Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol. 2002; 32(10): 2988-96[DOI][PubMed]
  • 23. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993; 91(4): 403-4[PubMed]
  • 24. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis. 2002; 34(2): 204-9[DOI][PubMed]
  • 25. Taghizade-Mortezaee F, Hashemzadeh-Chaleshtori M, Kheiri S, Parvin N, Norbakhsh M, Etemadi S, et al. Association of Interleukin-1β (IL-1β) Gene Polymorphisms with Uterine Leiomyoma. Zahedan J Res Med Sci. 2012; 14(7): 53-6
  • 26. Chun S, Kim H, Ku SY, Suh CS, Kim SH, Kim JG. The association between endometriosis and polymorphisms in the interleukin-1 family genes in Korean women. Am J Reprod Immunol. 2012; 68(2): 154-63[DOI][PubMed]
  • 27. Hsieh YY, Chang CC, Tsai FJ, Wu JY, Shi YR, Tsai HD, et al. Polymorphisms for interleukin-1 beta (IL-1 beta)-511 promoter, IL-1 beta exon 5, and IL-1 receptor antagonist: nonassociation with endometriosis. J Assist Reprod Genet. 2001; 18(9): 506-11[PubMed]
  • 28. Wen J, Deng L, Zhang XM. [Research on relationship between gene polymorphisms of interleukin-1 family and endometriosis]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006; 35(6): 653-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments